Repositioning Candidate Details
| Candidate ID: | R0794 |
| Source ID: | DB05426 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Talactoferrin alfa |
| Synonyms: | Talactoferrin alfa; Talactoferrin alpha |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation. |
| CAS Number: | 308240-58-6 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Oral talactoferrin stimulated the production of the immunostimulatory cytokine IL-18 in mice, increasing IL-18 levels both in the gut and in systemic circulation. Oral talactoferrin was also shown to stimulate the activity of NK cells and to increase the production and activity of key circulating immune cells. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
